ストックスクリーナーアプリを入手
27.81
4.47%
1.19
前日終値:
$26.62
開ける：
$27.27
24時間の取引高:
453.81K
Relative Volume:
0.87
時価総額：
$1.35B
収益：
-
当期純損益:
-
株価収益率:
-
EPS:
-
ネットキャッシュフロー:
-
1週間 パフォーマンス:
-8.25%
1か月 パフォーマンス:
-9.82%
6か月 パフォーマンス:
+109.26%
1年 パフォーマンス:
+46.45%
1日の値動き範囲:
$26.78
$28.51
1週間の範囲:
$25.23
$30.61
52週間の値動き範囲:
$5.485
$32.64
Oruka Therapeutics Inc Stock (ORKA) Company Profile
ORKA を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ORKA
Oruka Therapeutics Inc
|
27.81 | 1.29B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.15 | 118.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
812.27 | 81.61B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
422.50 | 53.69B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.94 | 49.49B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
176.00 | 37.34B | 447.02M | -1.18B | -906.14M | -6.1812 |
Oruka Therapeutics Inc Stock (ORKA) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-12-18 | 開始されました | Piper Sandler | Overweight |
| 2025-11-13 | 開始されました | Jefferies | Buy |
| 2025-10-27 | 開始されました | Guggenheim | Buy |
| 2025-10-13 | 開始されました | Barclays | Overweight |
| 2025-05-22 | 開始されました | BTIG Research | Buy |
| 2025-02-04 | 開始されました | Wolfe Research | Outperform |
| 2024-10-11 | 開始されました | Stifel | Buy |
| 2024-10-07 | 開始されました | H.C. Wainwright | Buy |
| 2024-09-17 | 開始されました | Leerink Partners | Outperform |
| 2024-09-16 | 開始されました | TD Cowen | Buy |
| 2024-09-13 | 開始されました | Jefferies | Buy |
| 2018-02-27 | 開始されました | Ascendiant Capital Markets | Buy |
| 2013-10-09 | 開始されました | Dawson James | Buy |
すべてを表示
Oruka Therapeutics Inc (ORKA) 最新ニュース
Oruka Therapeutics stock initiated with Buy rating at UBS on cancer drug potential - Investing.com Canada
Oruka Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - The Manila Times
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Oruka Therapeutics: ORKA-001 For Psoriasis In Focus As 2026 Phase 2 Data Nears - Seeking Alpha
ORKA-001 psoriasis trial: Fresh phase 2 update and what it means for investors - MSN
Oruka Therapeutics (NASDAQ:ORKA) Trading Down 8.3%What's Next? - MarketBeat
Oruka Therapeutics Builds Oncology Programs at Molecular Level - Kalkine Media
Insider Sell Alert: Laura Sandler Sells 13,000 Shares of Oruka T - GuruFocus
Oruka Therapeutics COO Sandler sells $370,795 in shares By Investing.com - Investing.com Canada
Oruka Therapeutics COO Sandler sells $370,795 in shares - Investing.com UK
Oruka Therapeutics (NASDAQ:ORKA) Stock Price Up 4.3% – Time to Buy? - Defense World
Oruka Therapeutics (NASDAQ:ORKA) Shares Up 4.3%Should You Buy? - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Trading Down 3.3%Time to Sell? - MarketBeat
Wolfe Research Initiates Coverage of Oruka Therapeutics (ORKA) with Outperform Recommendation - MSN
Rigel Pharmaceuticals (NASDAQ:RIGL) and Oruka Therapeutics (NASDAQ:ORKA) Financial Survey - Defense World
Oruka Therapeutics inks exclusive license deal with Paragon - MSN
Oruka Therapeutics (ORKA): Valuation Check After Board Appointment of Commercial Veteran Chris Martin - Sahm
Oruka Therapeutics (NASDAQ:ORKA) Reaches New 12-Month HighHere's What Happened - MarketBeat
Oruka Therapeutics stock hits 52-week high at 32.31 USD By Investing.com - Investing.com Australia
Oruka Therapeutics stock hits 52-week high at 32.31 USD - Investing.com India
Is Oruka Therapeutics Inc. (HQ1) stock undervalued historicallyMarket Sentiment Report & Fast Exit Strategy with Risk Control - Улправда
Financial Enhancement Group LLC Takes Position in Oruka Therapeutics, Inc. $ORKA - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Insider Sells $214,270.00 in Stock - MarketBeat
Oruka Therapeutics (NASDAQ:ORKA) Shares Up 11.3%Here's What Happened - MarketBeat
Why Oruka Therapeutics Inc. stock is a must watch in 2025Recession Risk & Real-Time Chart Pattern Alerts - DonanımHaber
Piper Sandler Begins Coverage on Oruka Therapeutics (NASDAQ:ORKA) - MarketBeat
How Oruka Therapeutics Inc. stock compares to growth peersWeekly Gains Report & AI Based Buy and Sell Signals - Улправда
Is Oruka Therapeutics Inc. stock a dividend growth opportunityJuly 2025 PreEarnings & Weekly Chart Analysis and Trade Guides - Улправда
ORKA-001 Psoriasis Trial: Fresh Phase 2 Update and What It Means for Investors - TipRanks
Oruka Therapeutics Earnings Notes - Trefis
Braidwell LP Cuts Stake in Oruka Therapeutics, Inc. $ORKA - MarketBeat
Oruka Therapeutics appoints Chris Martin to board of directors By Investing.com - Investing.com India
Oruka Therapeutics, Inc. (NASDAQ:ORKA) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Oruka Therapeutics appoints Chris Martin to board of directors - Investing.com
Oruka Therapeutics Appoints Christopher Martin to Board - TipRanks
Oruka Therapeutics Announces New Board Member and Board Transition - The Manila Times
B Group Inc. Increases Position in Oruka Therapeutics, Inc. $ORKA - Defense World
Oruka Therapeutics (ORKA) Stock Analysis Report | Financials & Insights - Benzinga
Oruka Therapeutics, Inc. $ORKA Shares Purchased by Geode Capital Management LLC - Defense World
Oruka Therapeutics, Inc. $ORKA Shares Purchased by Affinity Asset Advisors LLC - Defense World
Oruka Therapeutics (NASDAQ:ORKA) Sets New 52-Week HighWhat's Next? - MarketBeat
Oruka Therapeutics stock hits 52-week high, reaching $31.01 By Investing.com - Investing.com Nigeria
Can Oruka Therapeutics Inc. stock deliver consistent earnings growthCEO Change & AI Based Buy and Sell Signals - Newser
Will Oruka Therapeutics Inc. stock sustain high P E ratios2025 Volatility Report & Safe Capital Growth Plans - Newser
Is Oruka Therapeutics Inc. (HQ1) stock dividend growth reliable2025 Risk Factors & Consistent Profit Trading Strategies - Newser
Oruka Therapeutics stock hits 52-week high, reaching $31.01 - Investing.com
Should I hold or sell Oruka Therapeutics Inc. stock in 2025Market Movement Recap & AI Based Buy and Sell Signals - Newser
Is Oruka Therapeutics Inc. (HQ1) stock undervalued at current priceJuly 2025 Snapshot & Community Verified Trade Alerts - Newser
Is Oruka Therapeutics Inc. (HQ1) stock a momentum leaderQuarterly Portfolio Review & Long-Term Safe Investment Plans - Newser
Will Oruka Therapeutics Inc. stock see insider buyingMarket Growth Review & Consistent Profit Trading Strategies - Newser
Oruka Therapeutics Inc (ORKA) 財務データ
Oruka Therapeutics Inc (ORKA) の財務データはありません。詳細については、他の銘柄を確認してください。
収益
当期純利益
現金流量
EPS
28.63%
大文字化:
|
ボリューム (24 時間):